S. Luelmo

发表

Remission of psoriasis during treatment with sorafenib

C. Blank, R. van Doorn, M. Vermeer, 2018, JAAD case reports.

Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer.

W. Mesker, A. Vahrmeijer, H. Versteeg, 2021, Thrombosis research.

Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies.

H. Lamb, J. Kroep, S. Osanto, 2019, The oncologist.

Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial

M. V. van Oijen, M. den Dulk, G. Patijn, 2020, Trials.

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

A. Zwinderman, C. Punt, G. Patijn, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying the Need to Discuss Infertility Concerns Affecting Testicular Cancer Patients: An Evaluation (INDICATE Study)

H. Putter, H. Elzevier, R. Pelger, 2021, Cancers.

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

A. Zwinderman, C. Punt, G. Patijn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up

F. Dekker, H. Morreau, J. V. van Hooft, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer

S. Osanto, S. Luelmo, 2017 .

Phase II Study of Everolimus and Capecitabine in Patients with Locally advanced or Metastatic Hepatocellular Carcinoma (HCC). Results of the first 10 Patients Included

N. Weijl, S. Osanto, S. Luelmo, 2012 .

The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis.

M. Sprangers, M. V. van Oijen, C. V. van Eijck, 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association.

No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: A randomized, placebo-controlled study

J. V. van Dissel, M. Versteegh, P. Ros, 2002, Critical care medicine.

The self-perceived palliative care barriers and educational needs of clinicians working in hospital primary care teams and referral patterns: lessons learned from a single-center survey and cohort study.

Y. M. van der Linden, N. Horeweg, S. Luelmo, 2021, Annals of palliative medicine.

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy

L. de Geus-Oei, A. Windhorst, P. Kuppen, 2021, Cancers.

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.

H. McLeod, S. Houterman, H. Gelderblom, 2022, European journal of cancer.

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

C. V. van Eijck, J. D. de Groot, L. Mekenkamp, 2021, Therapeutic advances in medical oncology.

Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients

C. V. van Eijck, L. Mekenkamp, M. Besselink, 2022, Frontiers in Immunology.

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study

C. V. van Eijck, J. D. de Groot, L. Mekenkamp, 2021, International journal of molecular sciences.

Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer

B. G. Sibinga Mulder, H. Morreau, A. Vahrmeijer, 2016, Journal of Clinical Pathology.

The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study)

W. Vervenne, H. Gelderblom, C. V. van Herpen, 2019, Clinical pharmacology and therapeutics.

Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers

B. G. Sibinga Mulder, H. Morreau, T. Potjer, 2018, European Journal of Human Genetics.

Diagnostic value of targeted next-generation sequencing in patients with suspected pancreatic or periampullary cancer

B. G. Sibinga Mulder, H. Morreau, A. Vahrmeijer, 2017, Journal of Clinical Pathology.

A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?

W. Vervenne, H. Gelderblom, W. V. D. Graaf, 2019, Journal of Clinical Oncology.

The prognostic value of the 12‐, 6‐, 3‐ and 1‐month ‘Surprise Question’ in cancer patients: A prospective cohort study in three hospitals

D. Nieboer, A. van der Heide, Y. M. van der Linden, 2022, European journal of cancer care.

Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers

B. G. Sibinga Mulder, H. Morreau, T. Potjer, 2018, European Journal of Human Genetics.

Increasing Systemic Immune-Inflammation Index During Treatment in Patients with Advanced Pancreatic Cancer is Associated with Poor Survival - A Retrospective, Multicenter, Cohort Study.

C. V. van Eijck, B. Bonsing, J. Mieog, 2023, Annals of surgery.

Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient preference non-randomized trial

M. V. van Oijen, M. Los, M. Besselink, 2023, Acta oncologica.